Connect with us

Technology

Mass Spectrometry Market to Grow by USD 3.52 Billion from 2024-2028, Driven by Hyphenated Technology and AI Advancements – Technavio Report

Published

on

NEW YORK, Sept. 6, 2024 /PRNewswire/ — Report with market evolution powered by AI- The global mass spectrometry market size is estimated to grow by USD 3.52 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 12.26%during the forecast period. Increase in use of hyphenated technology is driving market growth, with a trend towards increasing demand for mass spectrometers in personalized medicine. However, high cost of mass spectrometry instrumentsposes a challenge. Key market players include 908 Devices Inc., ABB Ltd., Agilent Technologies Inc., Bruker Corp., Endress Hauser Group Services AG, European Virtual Institute for Speciation Analysis, JEOL Ltd., Kore Technology Ltd., LECO Corp., PerkinElmer Inc., Rigaku Corp., Shimadzu Corp., Teledyne Technologies Inc., Thermo Fisher Scientific Inc., and Waters Corp..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report

Mass Spectrometry Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 12.26%

Market growth 2024-2028

USD 3520 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

10.58

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 43%

Key countries

US, Canada, Germany, China, and UK

Key companies profiled

908 Devices Inc., ABB Ltd., Agilent Technologies Inc., Bruker Corp., Endress Hauser Group Services AG, European Virtual Institute for Speciation Analysis, JEOL Ltd., Kore Technology Ltd., LECO Corp., PerkinElmer Inc., Rigaku Corp., Shimadzu Corp., Teledyne Technologies Inc., Thermo Fisher Scientific Inc., and Waters Corp.

Market Driver

Personalized medicine is a patient-centric approach to healthcare that tailors treatment to individual characteristics, improving disease diagnosis and treatment effectiveness. Predictive diagnostics, a key aspect of personalized medicine, can predict human pathologies and aid in early detection and treatment. Misdiagnosis, a significant issue in healthcare, affects millions, leading to delayed or inappropriate treatment and potential harm to patients. Mass spectrometers play a crucial role in personalized medicine by screening biomarkers for disease phenotypes, enabling targeted drug development and individualized therapy. The growing popularity of mass spectrometers in personalized medicine is expected to increase demand, driving market growth. With healthcare spending contributing significantly to overall expenditures in major economies, cost savings through accurate diagnosis are a major incentive. The Thermo Fisher Scientific HDX-Mass spectrometer, with high-quality information and compact, stable ionization technology, is an example of advances in mass spectrometry systems for personalized medicine.

The Mass Spectrometry market is experiencing significant growth, driven by increasing spending on pharmaceuticals and biopharmaceuticals. Drug safety is a key focus area, with assumptions around the importance of personalized medicine and drug discovery in late-stage development and clinical trials. Emerging countries and greenfield projects present new opportunities, requiring skilled professionals for method development, validation, operation, and troubleshooting activities. The market ecosystem includes software & services, with LC-MS, GC-MS, and ICP-MS segments leading the way. Environmental testing, food testing, clinical diagnostics, and applied industries also contribute. Metabolomics, vaccine development, and the petroleum sector are emerging research fields. CFI funding and companies like SCIEX AB and Thermo Fisher Scientific drive innovation in mass spectrometry technology. MS analysis provides high resolution, with background intrusion, fragmentation patterns, isotopic abundance, and chemical data crucial for accurate results. Software tools and algorithms enhance research capabilities, with advanced tools essential for Triple Quadrupole and Quadrupole TOF applications.

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

Mass spectrometers are essential analytical tools with advanced features that come at a high price tag, averaging between USD1,000 and USD100,000. The cost of ownership goes beyond the initial investment, as maintenance, service, and repair add to the expense. Annual maintenance costs can range from 10% to 20% of the instrument’s price, depending on the brand and type. These instruments require regular upkeep due to pressure and temperature changes, mechanical stress, and optical decay. Proper use guidelines are crucial to prevent contamination and maintain performance accuracy. The significant investment and ongoing maintenance costs may hinder the growth of the global mass spectrometry market during the forecast period.The Mass Spectrometry (MS) market is a dynamic and growing ecosystem, driven by advancements in MS technology and its applications across various industries. Key segments include Software & Services, LC-MS, GC-MS, ICP-MS, and others. Environmental testing, food testing, clinical diagnostics, applied industries, metabolomics, petroleum sector, and forensics are major application areas. Companies like SCIEX AB and Thermo Fisher Scientific lead the market. Challenges include background intrusion, fragmentation patterns, isotopic abundance, and laboratory safety measures. High-resolution MS analysis is crucial for accurate chemical data. Triple Quadrupole and Quadrupole TOF instruments are popular for MS analysis. Advanced software tools and algorithms are essential for research fields like vaccine development and precision healthcare. Components like chromatography, spectroscopy, imaging, and liquid chromatography (LC) and gas chromatography (GC) are integral to MS technology. Hybrid mass spectrometry, Triple quadrupole instruments, and Multiple Reaction Monitoring are advanced techniques. Biomarkers, metabolites, drug compounds, and patient samples are common MS analysis targets. CFI funding and research collaborations continue to fuel innovation in MS technology.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview

This mass spectrometry market report extensively covers market segmentation by

End-user1.1 Pharmaceutical and biotechnology industries1.2 Chemical and petrochemical industries1.3 OthersProduct2.1 Instruments2.2 Consumables and servicesGeography3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Pharmaceutical and biotechnology industries- Mass spectrometry is a valuable analytical tool used in various industries, including pharmaceuticals and biotechnology, to determine the molecular structure and purity of samples. In pharmaceuticals, it is employed to analyze therapeutic agents, characterize intermolecular interactions for drug discovery, and ensure the right compound is manufactured. The increasing demand for personalized medicine and monoclonal antibodies has further boosted the market. In biotechnology, mass spectrometry provides extensive information about biologically important low-molecular-weight species, such as bacteria and viruses, and is used to evaluate the quality of biologics and biosimilars. Additionally, it is used to characterize metabolic status in microbial fermentations. Government investments in the pharmaceutical and biotechnology industries will drive market growth, particularly in emerging countries in APAC, due to the establishment of innovative facilities and cheap labor.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

The Mass Spectrometry (MS) market is poised for significant growth due to increasing spending on pharmaceutical research and development, with a particular focus on biopharmaceuticals and personalized medicine. MS analysis plays a crucial role in drug safety assessment, providing high-resolution data on fragmentation patterns, isotopic abundance, and chemical data. Background intrusion and accurate mass measurement are key challenges in MS, requiring advanced software tools and algorithms for data processing. MS is also essential in forensics, vaccine development, and laboratory safety measures. Chromatography techniques, such as Liquid Chromatography (LC), are often used in conjunction with MS for sample preparation and separation. Spectroscopy and imaging applications are also expanding the scope of MS technology. Overall, the market for MS components and systems is expected to grow robustly due to the versatility and importance of MS in various industries.

Market Research Overview

The Mass Spectrometry (MS) market is experiencing significant growth due to increasing spending on pharmaceutical research and development, particularly in biopharmaceuticals and drug discovery. The market is driven by the demand for drug safety and personalized medicine, leading to an increase in late-stage development and clinical trials. Emerging countries are also contributing to the growth of the MS market with the establishment of greenfield projects and the availability of skilled professionals. Method development, validation, operation, and troubleshooting activities are key aspects of MS analysis, which includes Liquid Chromatography-Mass Spectrometry (LC-MS), Gas Chromatography-Mass Spectrometry (GC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS), and other MS techniques. The market ecosystem includes software & services, environmental testing, food testing, clinical diagnostics, applied industries, metabolomics, petroleum sector, and more. MS technology is used in various research fields such as metabolomics, vaccine development, and forensics. Advanced software tools and algorithms are essential for MS analysis, including Triple Quadrupole, Quadrupole TOF, and High Resolution Mass Spectrometry. MS analysis involves identifying fragmentation patterns, isotopic abundance, and chemical data to understand the background intrusion and drug compounds in patient samples. Laboratory safety measures, chromatography, spectroscopy, imaging, and hybrid mass spectrometry are also important aspects of the MS market. Triple quadrupole instruments and Multiple Reaction Monitoring are widely used for precision healthcare, biomarkers, metabolites, and drug compounds. The MS market is expected to continue growing due to the increasing demand for advanced MS technology in various industries.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

End-userPharmaceutical And Biotechnology IndustriesChemical And Petrochemical IndustriesOthersProductInstrumentsConsumables And ServicesGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/mass-spectrometry-market-to-grow-by-usd-3-52-billion-from-2024-2028–driven-by-hyphenated-technology-and-ai-advancements—technavio-report-302239726.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Asian American Engineer of the Year Award and Conference Announces First Phase of 2025-2026 Awardees

Published

on

By

SANTA CLARA, Calif., May 1, 2026 /PRNewswire/ — The Asian American Engineer of the Year Award (AAEOY) Executive Committee announces the AAEOY 2025-2026 first phase awardees as follows:

Distinguished Lifetime Achievement Award

Mr. Lip-Bu Tan, CEO, Intel Corporation

Distinguished Leadership in Science and Technology Award

Dr. Arun Majumdar, Dean of the Stanford Doerr School of Sustainability, Stanford University

Executive of the Year Award

Dr. Xiaodong Che, Chief Technology Officer, Western DigitalDr. Sam Heidari, CEO, LumotiveDr. Jungwon Lee, Corporate Executive Vice President, Samsung ElectronicsDr. Liu Ren, Vice President & Chief Scientist, Bosch ResearchMr. Brandon Wang, Vice President, Synopsys

Engineer of the Year Award

Ms. Vivian Ye, Principal Member of Technical Staff, AT&T

Most Promising Engineer of the Year Award

Mr. Max Fang, Director of Architecture, AmbarellaMr. Johnny Ho, CSO & Co-founder, Perplexity AI

The AAEOY Award has been presented annually since 2002 as a cornerstone of the National Engineers Week program, honoring distinguished Asian American professionals across academia, public service, and industry. Since its inception, the AAEOY has recognized over 300 honorees — including nine Nobel Laureates, pioneering scholars, prominent corporate executives, and an astronaut — serving as a beacon of inspiration for the global STEM community. After a series of impactful ceremonies nationwide, the 2025-2026 AAEOY Award and Conference returns to the heart of innovation in Silicon Valley at the Santa Clara Convention Center on September 18-19, 2026.

For more information regarding the AAEOY program, awardees, and event registration, please visit www.aaeoy.org.

The Chinese Institute of Engineers in USA (CIE-USA), founded in 1917, is a nonprofit professional organization that promotes science, technology, engineering, and mathematics (STEM); supports professional advancement and leadership development; and recognizes the achievements of Asian American professionals through flagship programs such as the Asian American Engineer of the Year (AAEOY) Awards. One of the oldest and most prestigious Chinese American engineering associations in the United States, CIE-USA has seven regional chapters nationwide and hosts events throughout the year.

View original content to download multimedia:https://www.prnewswire.com/news-releases/asian-american-engineer-of-the-year-award-and-conference-announces-first-phase-of-2025-2026-awardees-302760569.html

SOURCE AAEOY

Continue Reading

Technology

Larry Kellerman, Fermi’s Chief Power Officer and Architect of Its 17 GW Energy Infrastructure, Accepts Board Nomination

Published

on

By

DALLAS, May 1, 2026 /PRNewswire/ — Toby Neugebauer, co-founder and largest shareholder of Fermi America (NASDAQ & LSE: FRMI), today announced that he has nominated Larry Kellerman to join the Fermi Board of Directors. Kellerman, who serves as Chief Power Officer at Fermi America, is the architect of the Company’s 17-gigawatt powered data center campus in Amarillo, Texas — the largest private energy grid in America.

Kellerman is co-founder and Managing Partner of Twenty First Century Utilities and brings more than four decades of power industry and finance expertise to the role. His career spans senior leadership positions at Goldman Sachs, El Paso Corporation, and I Squared Capital. Kellerman said he was honored by the nomination and would be pleased to serve if approved by the Board.

“I appreciate everything that Toby has manifested in Fermi and know that no other human could have created the enterprise and its many thoughtfully interconnected elements as quickly, as effectively, and in as value-accretive a manner as Toby’s leadership has been able to deliver.”
— Larry Kellerman, Chief Power Officer and Board Nominee, Fermi America

For Neugebauer, the choice was crystal clear. Kellerman, who has worked alongside Neugebauer since the earliest days of Project Matador knows Fermi’s power story better than anyone.

“When I came up with the idea of Project Matador, I knew that Larry Kellerman was the one person I needed to convert a really great idea into a really great reality. His knowledge of power and the future of powering data centers is unmatched. Larry is uniquely qualified to steward Fermi as a Board member, and I couldn’t be more pleased with his willingness to serve.”
— Toby Neugebauer, Co-Founder, Fermi America

View original content:https://www.prnewswire.com/news-releases/larry-kellerman-fermis-chief-power-officer-and-architect-of-its-17-gw-energy-infrastructure-accepts-board-nomination-302760575.html

SOURCE Toby Neugebauer

Continue Reading

Technology

EAST SIDE GAMES GROUP ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OF UNITS TO RAISE UP TO $3.5 MILLION

Published

on

By

VANCOUVER, BC, May 1, 2026 /CNW/ – East Side Games Group (TSX: EAGR) (OTC: EAGRF) (the “Company”), Canada’s leading free-to-play mobile game group, announces a non-brokered private placement of 31,818,182  units (a “Unit”) at $0.11 per Unit (the “Unit Price”), for total gross proceeds of up to $3.5 million. 

Each Unit will be comprised of one common share and one full whole warrant (a “Warrant”).  Each whole Warrant will be exercisable at $0.14 per share (the “Exercise Price”) for a period of three years from issuance. The Warrants will be subject to standard anti-dilution adjustments.

The private placement will be offered in reliance on prospectus exemptions, and any securities sold will be subject to a four month statutory hold period.  The private placement is not anticipated to have any material impact on the control of the Company, nor is it anticipated that any new control persons would be created as a result of the private placement.

It is anticipated that Derek Lew, a director of the Company, will participate in the private placement for an amount of $1.0 million for 9,090,909 Units. As at the date of this news release, Mr. Lew holds 1,667,244 common shares of the Company (2.17%). If the private placement is completed as anticipated, Mr. Lew will hold 10,758,153 common shares (representing 9.89% of the common shares anticipated to be outstanding upon completion of the private placement on a partially diluted basis), 9,090,909 Warrants and 250,000 incentive stock options. Upon exercise of his Warrants, Mr. Lew would own 19,849,062 common shares representing 16.84% of the then issued and outstanding common shares assuming no other share issuances.

The TSX Company Manual requires shareholder approval be obtained  for private placements if the maximum number of common shares issuable under the private placement represents an amount that is more than 25% of the total outstanding common shares as at the date of the press release (pursuant to Section 607(g)). Disinterested shareholder approval must be obtained (excluding those shareholders participating in this private placement and their associates and affiliates) if the number of common shares issued and issuable to insiders under a private placement exceeds 10% of the Company’s issued and outstanding common shares as of the date hereof (pursuant to Section 607(g)(ii)).

As: (a) the private placement is for up to 31,818,182 Units (being equivalent to 41.35% of the Company’s outstanding shares as at the date of this press release), (b) Mr. Lew’s subscription for 9,090,909 Units represents an amount that is equivalent to 11.81% of the Company’s outstanding shares as at the date of this press release, and (c) the Warrants comprising the Units have an exercise price of $0.14 per share (and the five day VWAP is $0.144 per share), the Company has obtained written consent from Jason Bailey, the Company’s CEO and a director, in support of the private placement in accordance with Section 604(d) of the TSX Company Manual.  Mr. Bailey holds more than 50% of the Company’s outstanding shares as at the date of this press release.

The net proceeds from the private placement will be used to repay indebtedness owing to the Royal Bank of Canada (RBC) and for operating expenses and general working capital. Mr. Bailey commented, “With this funding in place, we are on solid footing to continue our disciplined approach to completing the business’s turnaround. With our core portfolio of well performing titles, we have a solid foundation to rebuild upon. We feel we have a strong runway, pipeline and team to execute toward a positive 2026,” [and] “I’d like to thank our existing shareholders for their support and guidance through a difficult 2025 and look forward to achieving the results that will allow this Company, our capital markets strategy and employees to reach its potential.”

The Company’s board of directors considers the private placement to be in the best interests of its shareholders, after having taken into account other alternative forms of financing.  In the course of its review, the Company considered other replacement debt financing, the Company’s ongoing cashflow from operations, as well as ongoing operating expenses, one-off necessary expenditures and the Company’s debt load, within the larger context of the analysis detailed in its press release dated March 31, 2026 as to the re-orienting of the Company’s overall business strategy. 

The Company anticipates that the private placement will close on or before May 8, 2026, subject to acceptance by the TSX.

The Company reserves the right to pay finder’s fees in the form of common shares (in lieu of cash fees) and broker warrants to arm’s length finders in connection with the private placement to arm’s length parties, in accordance with TSX policies. No finder’s fee will be paid to any non-arm’s length parties, nor with respect to subscriptions from non-arm’s length parties.  A maximum number of 1,363,636 common shares (to be issued at $0.11 per share for a total value of $150,000) and a maximum number of 1,254,545 broker warrants will be issuable, assuming the private placement is fully subscribed.  Each broker warrant will entitle the holder to acquire one common share at $0.14 per common share (the “Broker Warrant Exercise Price”) for a period of three years form issuance.  

The maximum number of securities issuable under the private placement is 66,254,545 common shares, comprising 31,818,182 common shares comprising the Units, 31,818,182 common shares issuable upon exercise of the Warrants, 1,363,636 common shares to be issued as finder’s fees, and 1,254,545 common shares issuable upon exercise of the broker warrants, which represents an amount equivalent to 86.10% of the total outstanding common shares as at the date of this press release on a non-diluted basis, without taking into effect the private placement itself, or approximately 46.27% of the Company’s total issued and outstanding common shares following completion of the private placement (being 143,200,825 shares anticipated to be outstanding on a partially diluted basis, assuming the private placement is fully subscribed, full issuance of the finder’s fee shares and full exercise of the Warrants and broker warrants). The Unit Price represents a 22% discount to the Company’s five-day volume-weighted trading price of its common shares on the TSX as at the time of submitting the Company’s application to TSX (the “Market Price”). Market Price and the Exercise Price and the Broker Warrant Exercise Price represent a 2.47% discount to the Market Price.

The total number of common shares expected to be issued to insider (Mr. Lew) under the private placement is 18,181,818 (consisting of 9,090,909 common shares and 9,090,909 common shares issuable upon full exercise of Warrants), representing 23.63% of the total outstanding common shares as at the date of this press release on a non-diluted basis, without taking into effect the private placement itself, or 12.70% of the Company’s total issued and outstanding common shares following completion of the private placement (being 143,200,825 shares anticipated to be outstanding on a partially diluted basis, assuming the private placement is fully subscribed, full issuance of the finder’s fee shares and full exercise of the Warrants and the broker warrants).

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States.  The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United states or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration is available.

ABOUT EAST SIDE GAMES GROUP

ESGG is a leader in free-to-play mobile gaming, thrilling players with unforgettable experiences that spark lifelong fandom. Fueled by an entrepreneurial spirit, we are driven by creativity, flawless execution, and a laser-focused strategy. We develop and publish both original and licensed IP titles, license our cutting-edge GameKit(s) platforms, and strategically acquire studios or games to expand our family.

Headquartered in Vancouver with around 100 talent-dense team members, we operate over a dozen titles under East Side Games (“ESG”) and LDRLY (Technologies) Inc. (“LDRLY”). Together, we’re crafting, launching, and publishing mobile games across our own studios and an extended Game Kit partner network-reaching players on iOS and Android worldwide.

We power our success through in-app purchases (“IAP”) — offering exclusive, game-enhancing virtual items — and in-game advertising. To keep growing, we focus on captivating audiences, keeping them engaged, and unlocking exciting new ways to monetize. We’ll drive this momentum by launching bold new titles, enriching our current lineup, innovating discovery, expanding into fresh markets, and exploring new distribution platforms.

Additional information about the Company continues to be available under its legal name, East Side Games Group Inc., at www.sedarplus.ca.

Forward-looking Information

Certain statements in this news release constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are often, but not always, identified by the use of words such as “expects,” “anticipates,” “plans,” “intends,” “believes,” “estimates,” “projects,” “may,” “will,” “would,” “could,” “should,” and similar expressions. Forward-looking statements in this news release include, without limitation, statements regarding the proposed private placement.

Forward-looking statements are based on management’s current expectations, estimates, projections and assumptions. Such forward-looking statements are subject to significant risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied by such statements, including, without limitation, risks relating to the Company’s ability to complete the proposed private placement as described, and relating to general economic, market and industry conditions. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

SOURCE East Side Games Group Inc.

Continue Reading

Trending